Sanofi-Aventis Hits Trail Blazing 42 Percent Growth In April As Indian Drug Market Sprints By 24 Percent
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - June is a keenly awaited month for large and small pharmaceutical companies operating in India as it signals the onset of a long spell of the monsoon season bringing in the rains and effectively meaning peak sales for drug companies riding on the surge in demand in a broad range of anti-infective and common cold and cough drugs
You may also be interested in...
Ajay Piramal Aims At Lead Ranks In CRAMS, OTC And Critical Care Business; Reveals Details On Abbott Deal
MUMBAI - Giving up one flourishing unit seems to have created larger business opportunities for a few others that form part of Indian industrialist Ajay Piramal's enterprise Piramal Healthcare
Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis Managing Director Shailesh Ayyangar faces the daunting challenge of creating a new paradigm in the rural centers of India. In a rare interview, Ayyangar spoke to PharmAsia News' India Bureau about the company's rural markets strategy, creating brands, doing deals and about buying out "strategically important" companies.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).